COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 1, 2012, Pages 49-63

  Cathcart, Mary Clare ^a   O'Byrne, Kenneth J ^a   Reynolds, John V ^a   O'Sullivan, Jacintha ^a   Pidgeon, Graham P ^a  

^a Dublin Molecular Medicine Centre   (Ireland)

Author keywords

Cancer; Colorectal; Cyclooxygenases; Esophagus; Prostanoids; Stomach

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTANOID; ROFECOXIB; THROMBOXANE A2;

BARRETT ESOPHAGUS; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; CARDIOTOXICITY; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG TARGETING; ENZYME METABOLISM; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; GASTROINTESTINAL NEOPLASMS; MOLECULAR TARGETED THERAPY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROSTAGLANDINS E; SIGNAL TRANSDUCTION;

EID: 80755184801     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.09.004     Document Type: Review

References (246)

1. W.H.O. Global action against cancer, World Health Organisation and International Union Against Cancer 2005, 1-24.
2. Greene E.R., Huang S., Serhan C.N., Panigrahy D. Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat. Aug 16 2011, (Electronic publication ahead of print).
3. Wang D., Dubois R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10:181-193.
4. Warner T.D., Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004, 18:790-804.
5. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13926-13931.
6. Snipes J.A., Kis B., Shelness G.S., Hewett J.A., Busija D.W. Cloning and characterization of cyclooxygenase-1b (putative cyclooxygenase-3) in rat. J. Pharmacol. Exp. Ther. 2005, 313:668-676.
7. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. J. Lipid Res. 2009, 50(Suppl):S423-S428.
8. Wu W.K., Sung J.J., Lee C.W., Yu J., Cho C.H. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010, 295:7-16.
9. Antonarakis E.S., Heath E.I., Walczak J.R., Nelson W.G., Fedor H., De Marzo A.M., Zahurak M.L., Piantadosi S., Dannenberg A.J., Gurganus R.T., Baker S.D., Parnes H.L., DeWeese T.L., Partin A.W., Carducci M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J. Clin. Oncol. 2009, 27:4986-4993.
10. Dragovich T., Burris H., Loehrer P., Von Hoff D.D., Chow S., Stratton S., Green S., Obregon Y., Alvarez I., Gordon M. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am. J. Clin. Oncol. 2008, 31:157-162.
11. Jakobsen A., Mortensen J.P., Bisgaard C., Lindebjerg J., Rafaelsen S.R., Bendtsen V.O. A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial. Int. J. Colorectal Dis. 2008, 23:251-255.
12. Papadimitrakopoulou V.A., William W.N., Dannenberg A.J., Lippman S.M., Lee J.J., Ondrey F.G., Peterson D.E., Feng L., Atwell A., El-Naggar A.K., Nathan C.O., Helman J.I., Du B., Yueh B., Boyle J.O. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin. Cancer Res. 2008, 14:2095-2101.
13. Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K., Nakamura S., Ogawa M., Sugiura T., Mitsudomi T., Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 1999, 5:1001-1005.
14. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001, 7:861-867.
15. Brabender J., Park J., Metzger R., Schneider P.M., Lord R.V., Holscher A.H., Danenberg K.D., Danenberg P.V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg. 2002, 235:440-443.
16. Edelman M.J., Watson D., Wang X., Morrison C., Kratzke R.A., Jewell S., Hodgson L., Mauer A.M., Gajra A., Masters G.A., Bedor M., Vokes E.E., Green M.J. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - cancer and leukemia group B trial 30203. J. Clin. Oncol. 2008, 26:848-855.
17. Fidler M.J., Argiris A., Patel J.D., Johnson D.H., Sandler A., Villaflor V.M., Coon J.t., Buckingham L., Kaiser K., Basu S., Bonomi P. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin. Cancer Res. 2008, 14:2088-2094.
18. Mutter R., Lu B., Carbone D.P., Csiki I., Moretti L., Johnson D.H., Morrow J.D., Sandler A.B., Shyr Y., Ye F., Choy H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin. Cancer Res. 2009, 15:2158-2165.
19. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
20. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352:1092-1102.
21. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352:1071-1080.
22. Heath E.I., Canto M.I., Piantadosi S., Montgomery E., Weinstein W.M., Herman J.G., Dannenberg A.J., Yang V.W., Shar A.O., Hawk E., Forastiere A.A. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J. Natl. Cancer Inst. 2007, 99:545-557.
23. Moody T.W., Leyton J., Zakowicz H., Hida T., Kang Y., Jakowlew S., You L., Ozbun L., Zia H., Youngberg J., Malkinson A. Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res. 2001, 21:1749-1755.
24. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 1998, 58:5354-5360.
25. Kisley L.R., Barrett B.S., Dwyer-Nield L.D., Bauer A.K., Thompson D.C., Malkinson A.M. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 2002, 23:1653-1660.
26. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343:1520-1528. 1522 p following 1528.
27. Pidgeon G.P., Tamosiuniene R., Chen G., Leonard I., Belton O., Bradford A., Fitzgerald D.J. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 2004, 110:2701-2707.
28. Cathcart M.C., Tamosiuniene R., Chen G., Neilan T.G., Bradford A., O'Byrne K.J., Fitzgerald D.J., Pidgeon G.P. Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J. Pharmacol. Exp. Ther. 2008, 326:51-58.
29. Funk C.D., FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol. 2007, 50:470-479.
30. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 2001, 108:25-30.
31. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94:252-266.
32. Yang V.W., Shields J.M., Hamilton S.R., Spannhake E.W., Hubbard W.C., Hylind L.M., Robinson C.R., Giardiello F.M. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. 1998, 58:1750-1753.
33. McLemore T.L., Hubbard W.C., Litterst C.L., Liu M.C., Miller S., McMahon N.A., Eggleston J.C., Boyd M.R. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988, 48:3140-3147.
34. Hubbard W.C., Alley M.C., Gray G.N., Green K.C., McLemore T.L., Boyd M.R. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res. 1989, 49:826-832.
35. Ermert L., Dierkes C., Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin. Cancer Res. 2003, 9:1604-1610.
36. Gilroy D.W., Tomlinson A., Willoughby D.A. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. J. Pharmacol. 1998, 355:211-217.
37. Morteau O., Morham S.G., Sellon R., Dieleman L.A., Langenbach R., Smithies O., Sartor R.B. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 2000, 105:469-478.
38. Dirig D.M., Isakson P.C., Yaksh T.L. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J. Pharmacol. Exp. Ther. 1998, 285:1031-1038.
39. Okahara K., Sun B., Kambayashi J. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1922-1926.
40. Schwab J.M., Beschorner R., Meyermann R., Gozalan F., Schluesener H.J. Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. J. Neurosurg. 2002, 96:892-899.
41. Murphy J.F., Fitzgerald D.J. Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. FASEB J. 2001, 15:1667-1669.
42. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
43. Patrignani P., Panara M.R., Greco A., Fusco O., Natoli C., Iacobelli S., Cipollone F., Ganci A., Creminon C., Maclouf J., et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 1994, 271:1705-1712.
44. Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Curr. Med. Chem. 2000, 7:1113-1120.
45. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., Breyer M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 1994, 94:2504-2510.
46. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 1993, 268:9049-9054.
47. Asano K., Nakamura H., Lilly C.M., Klagsbrun M., Drazen J.M. Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells. J. Clin. Invest. 1997, 99:1057-1063.
48. Shemesh M., Gurevich M., Mizrachi D., Dombrovski L., Stram Y., Fields M.J., Shore L.S. Expression of functional luteinizing hormone (LH) receptor and its messenger ribonucleic acid in bovine uterine veins: LH induction of cyclooxygenase and augmentation of prostaglandin production in bovine uterine veins. Endocrinology 1997, 138:4844-4851.
49. Tamura M., Sebastian S., Gurates B., Yang S., Fang Z., Bulun S.E. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J. Clin. Endocrinol. Metab. 2002, 87:3504-3507.
50. Di Popolo A., Memoli A., Apicella A., Tuccillo C., di Palma A., Ricchi P., Acquaviva A.M., Zarrilli R. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000, 19:5517-5524.
51. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 1999, 5:1418-1423.
52. Pichiule P., Chavez J.C., LaManna J.C. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J. Biol. Chem. 2004, 279:12171-12180.
53. Lukiw W.J., Ottlecz A., Lambrou G., Grueninger M., Finley J., Thompson H.W., Bazan N.G. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest. Ophthalmol. Vis. Sci. 2003, 44:4163-4170.
54. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60:1306-1311.
55. Wang D., DuBois R.N. Measurement of eicosanoids in cancer tissues. Methods Enzymol. 2007, 433:27-50.
56. Bogatcheva N.V., Sergeeva M.G., Dudek S.M., Verin A.D. Arachidonic acid cascade in endothelial pathobiology. Microvasc. Res. 2005, 69:107-127.
57. Needleman P., Isakson P.C. Selective inhibition of cyclooxygenase-2. Sci. Med. 1998, 26-35.
58. Hata A.N., Breyer R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 2004, 103:147-166.
59. Alfranca A., Iniguez M.A., Fresno M., Redondo J.M. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc. Res. 2006, 70:446-456.
60. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395:137-143.
61. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43:527-550.
62. Conio M., Lapertosa G., Blanchi S., Filiberti R. Barrett's esophagus: an update. Crit. Rev. Oncol. Hematol. 2003, 46:187-206.
63. Altorki N.K., Oliveria S., Schrump D.S. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin. Surg. Oncol. 1997, 13:270-280.
64. Cameron A.J. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol. Clin. North Am. 1997, 26:487-494.
65. Long J.D., Orlando R.C. Eicosanoids and the esophagus. Prostaglandins Other Lipid Mediat. 2000, 61:91-104.
66. Stoner G.D., Wang L.S., Chen T. Chemoprevention of esophageal squamous cell carcinoma. Toxicol. Appl. Pharmacol. 2007, 224:337-349.
67. Ku G.Y., Ilson D.H. Esophagogastric cancer: targeted agents. Cancer Treat. Rev. 2010, 36:235-248.
68. W.H.O. GLOBOCAN 2008 fast stats, International Agency for Research on Cancer 2008, 1-8.
69. Fujimura T., Ohta T., Oyama K., Miyashita T., Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J. Gastroenterol. 2006, 12:1336-1345.
70. Howson C.P., Hiyama T., Wynder E.L. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol. Rev. 1986, 8:1-27.
71. Blot W.J., Devesa S.S., Kneller R.W., Fraumeni J.F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
72. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992, 52:6735-6740.
73. Romano M., Ricci V., Memoli A., Tuccillo C., Di Popolo A., Sommi P., Acquaviva A.M., Del Vecchio Blanco C., Bruni C.B., Zarrilli R. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J. Biol. Chem. 1998, 273:28560-28563.
74. Sung J.J., Leung W.K., Go M.Y., To K.F., Cheng A.S., Ng E.K., Chan F.K. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000, 157:729-735.
75. Powell S.M., Zilz N., Beazer-Barclay Y., Bryan T.M., Hamilton S.R., Thibodeau S.N., Vogelstein B., Kinzler K.W. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235-237.
76. Smith A.J., Stern H.S., Penner M., Hay K., Mitri A., Bapat B.V., Gallinger S. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res. 1994, 54:5527-5530.
77. D. Wang, R.N. Dubois, The role of COX-2 in intestinal inflammation and colorectal cancer, Oncogene 29 (2009) 781-788.
78. Morris C.D., Armstrong G.R., Bigley G., Green H., Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 2001, 96:990-996.
79. Cheong E., Ivory K., Doleman J., Parker M.L., Rhodes M., Johnson I.T. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 2004, 25:1945-1952.
80. Souza R.F., Shewmake K., Beer D.G., Cryer B., Spechler S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000, 60:5767-5772.
81. Vona-Davis L., Riggs D.R., Jackson B.J., McFadden D.W. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). J. Surg. Res. 2004, 119:143-148.
82. Yu H.P., Shi L.Y., Lu W.H., Su Y.H., Li Y.Y., Xu S.Q. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J. Gastroenterol. Hepatol. 2004, 19:638-642.
83. Buttar N.S., Wang K.K., Anderson M.A., Dierkhising R.A., Pacifico R.J., Krishnadath K.K., Lutzke L.S. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl. Cancer Inst. 2002, 94:422-429.
84. Buttar N.S., Wang K.K., Leontovich O., Westcott J.Y., Pacifico R.J., Anderson M.A., Krishnadath K.K., Lutzke L.S., Burgart L.J. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101-1112.
85. Li Z., Shimada Y., Kawabe A., Sato F., Maeda M., Komoto I., Hong T., Ding Y., Kaganoi J., Imamura M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 2001, 22:547-551.
86. Heath E.I., Canto M.I., Wu T.T., Piantadosi S., Hawk E., Unalp A., Gordon G., Forastiere A.A. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis. Esophagus 2003, 16:177-186.
87. Lanas A., Ortego J., Sopena F., Alcedo J., Barrio E., Bujanda L., Cosme A., Bajador E., Parra-Blanco A., Ferrandez A., Piazuelo E., Quintero E., Pique J.M. Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus. Aliment. Pharmacol. Ther. 2007, 26:913-923.
88. Kaur B.S., Khamnehei N., Iravani M., Namburu S.S., Lin O., Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002, 123:60-67.
89. Heeren P., Plukker J., van Dullemen H., Nap R., Hollema H. Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. Cancer Lett. 2005, 225:283-289.
90. Jimenez P., Piazuelo E., Cebrian C., Ortego J., Strunk M., Garcia-Gonzalez M.A., Santander S., Alcedo J., Lanas A. Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 2010, 31:440-451.
91. Kuramochi H., Vallbohmer D., Uchida K., Schneider S., Hamoui N., Shimizu D., Chandrasoma P.T., DeMeester T.R., Danenberg K.D., Danenberg P.V., Peters J.H. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J. Gastrointest. Surg. 2004, 8:1007-1016.
92. discussion 1016-1007.
93. Kase S., Osaki M., Honjo S., Hashimoto K., Adachi H., Tsujitani S., Ito H. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma. Pathobiology 2004, 71:84-92.
94. Saukkonen K., Rintahaka J., Sivula A., Buskens C.J., Van Rees B.P., Rio M.C., Haglund C., Van Lanschot J.J., Offerhaus G.J., Ristimaki A. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003, 111:915-925.
95. Sun W.H., Yu Q., Shen H., Ou X.L., Cao D.Z., Yu T., Qian C., Zhu F., Sun Y.L., Fu X.L., Su H. Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J. Gastroenterol. 2004, 10:2809-2813.
96. Lim H.Y., Joo H.J., Choi J.H., Yi J.W., Yang M.S., Cho D.Y., Kim H.S., Nam D.K., Lee K.B., Kim H.C. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 2000, 6:519-525.
97. J. Mrena, J.P. Wiksten, A. Kokkola, S. Nordling, A. Ristimaki, C. Haglund, COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer, Tumour Biol. 31 1-7.
98. Oshima H., Oshima M., Inaba K., Taketo M.M. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004, 23:1669-1678.
99. Oshima H., Matsunaga A., Fujimura T., Tsukamoto T., Taketo M.M., Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 2006, 131:1086-1095.
100. Chen C.N., Sung C.T., Lin M.T., Lee P.H., Chang K.J. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann. Surg. 2001, 233:183-188.
101. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
102. Williams C.S., Luongo C., Radhika A., Zhang T., Lamps L.W., Nanney L.B., Beauchamp R.D., DuBois R.N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996, 111:1134-1140.
103. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1:11-21.
104. Marnett L.J., DuBois R.N. COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 2002, 42:55-80.
105. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., Tiano H.F., Morham S.G., Smithies O., Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000, 60:4705-4708.
106. Eisinger A.L., Prescott S.M., Jones D.A., Stafforini D.M. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 2007, 82:147-154.
107. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993, 328:1313-1316.
108. Spagnesi M.T., Tonelli F., Dolara P., Caderni G., Valanzano R., Anastasi A., Bianchini F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994, 106:362-366.
109. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
110. Kitamura T., Itoh M., Noda T., Matsuura M., Wakabayashi K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int. J. Cancer 2004, 109:576-580.
111. Kitamura T., Kawamori T., Uchiya N., Itoh M., Noda T., Matsuura M., Sugimura T., Wakabayashi K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 2002, 23:1463-1466.
112. Niho N., Kitamura T., Takahashi M., Mutoh M., Sato H., Matsuura M., Sugimura T., Wakabayashi K. Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Cancer Sci. 2006, 97:1011-1014.
113. Wu W.K., Sung J.J., Wu Y.C., Li H.T., Yu L., Li Z.J., Cho C.H. Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells. Biochem. Biophys. Res. Commun. 2009, 382:79-84.
114. Ishikawa T.O., Herschman H.R. Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010, 31:729-736.
115. Fogli S., Banti I., Stefanelli F., Picchianti L., Digiacomo M., Macchia M., Breschi M.C., Lapucci A. Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells. Eur. J. Med. Chem. 2010, 45:5100-5107.
116. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122:518-523.
117. Park J.M., Kanaoka Y., Eguchi N., Aritake K., Grujic S., Materi A.M., Buslon V.S., Tippin B.L., Kwong A.M., Salido E., French S.W., Urade Y., Lin H.J. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Res. 2007, 67:881-889.
118. Ajuebor M.N., Singh A., Wallace J.L. Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G238-G244.
119. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., Wakabayashi K. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002, 62:28-32.
120. Zamuner S.R., Bak A.W., Devchand P.R., Wallace J.L. Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am. J. Pathol. 2005, 167:1293-1300.
121. Wang D., DuBois R.N. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett. 2008, 267:197-203.
122. Takashima T., Fujiwara Y., Hamaguchi M., Sasaki E., Tominaga K., Watanabe T., Oshitani N., Higuchi K., Arakawa T. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma. Oncol. Rep. 2005, 13:601-606.
123. Takashima T., Fujiwara Y., Higuchi K., Arakawa T., Yano Y., Hasuma T., Otani S. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int. J. Oncol. 2001, 19:465-471.
124. Konturek P.C., Kania J., Kukharsky V., Raithel M., Ocker M., Rembiasz K., Hahn E.G., Konturek S.J. Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. J. Pharmacol. Sci. 2004, 96:134-143.
125. Fu Y.G., Sung J.J., Wu K.C., Bai A.H., Chan M.C., Yu J., Fan D.M., Leung W.K. Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through the downregulation of angiopoietin-1. Cancer Lett. 2006, 243:246-254.
126. Leung W.K., Bai A.H., Chan V.Y., Yu J., Chan M.W., To K.F., Wu J.R., Chan K.K., Fu Y.G., Chan F.K., Sung J.J. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004, 53:331-338.
127. Ma X.M., Yu H., Huai N. Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma. World J. Gastroenterol. 2009, 15:3874-3883.
128. Chinery R., Coffey R.J., Graves-Deal R., Kirkland S.C., Sanchez S.C., Zackert W.E., Oates J.A., Morrow J.D. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res. 1999, 59:2739-2746.
129. Chen G.G., Lee J.F., Wang S.H., Chan U.P., Ip P.C., Lau W.Y. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci. 2002, 70:2631-2646.
130. Koyama M., Izutani Y., Goda A.E., Matsui T.A., Horinaka M., Tomosugi M., Fujiwara J., Nakamura Y., Wakada M., Yogosawa S., Sowa Y., Sakai T. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin. Cancer Res. 2010, 16:2320-2332.
131. Lin M.S., Chen W.C., Bai X., Wang Y.D. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J. Dig. Dis. 2007, 8:82-88.
132. Moriai M., Tsuji N., Kobayashi D., Kuribayashi K., Watanabe N. Down-regulation of hTERT expression plays an important role in 15-deoxy-Delta12,14-prostaglandin J2-induced apoptosis in cancer cells. Int. J. Oncol. 2009, 34:1363-1372.
133. Shimada T., Kojima K., Yoshiura K., Hiraishi H., Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002, 50:658-664.
134. Shin S.W., Seo C.Y., Han H., Han J.Y., Jeong J.S., Kwak J.Y., Park J.I. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin. Cancer Res. 2009, 15:5414-5425.
135. Su R.Y., Chi K.H., Huang D.Y., Tai M.H., Lin W.W. 15-deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol. Cancer Ther. 2008, 7:3429-3440.
136. Grau R., Iniguez M.A., Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. Cancer Res. 2004, 64:5162-5171.
137. Jang T.J., Min S.K., Bae J.D., Jung K.H., Lee J.I., Kim J.R., Ahn W.S. Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux. Gut 2004, 53:27-33.
138. von Rahden B.H., Stein H.J., Hartl S.A., Theisen J., Stigler B., Siewert J.R., Sarbia M. Expression of prostaglandin E synthase in Barrett's cancer. Dis. Esophagus 2008, 21:304-308.
139. Beales I.L., Ogunwobi O.O. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int. J. Cancer 2010, 126:2247-2255.
140. Gudis K., Tatsuguchi A., Wada K., Hiratsuka T., Futagami S., Fukuda Y., Kiyama T., Tajiri T., Miyake K., Sakamoto C. Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum. Pathol. 2007, 38:1826-1835.
141. Nakanishi M., Montrose D.C., Clark P., Nambiar P.R., Belinsky G.S., Claffey K.P., Xu D., Rosenberg D.W. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008, 68:3251-3259.
142. Stoner G.D., Qin H., Chen T., Carlton P.S., Rose M.E., Aziz R.M., Dixit R. The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis 2005, 26:1590-1595.
143. Deasy B.M., O'Sullivan-Coyne G., O'Donovan T.R., McKenna S.L., O'Sullivan G.C. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms. Cancer Lett. 2007, 256:246-258.
144. Lee J.J., Natsuizaka M., Ohashi S., Wong G.S., Takaoka M., Michaylira C.Z., Budo D., Tobias J.W., Kanai M., Shirakawa Y., Naomoto Y., Klein-Szanto A.J., Haase V.H., Nakagawa H. Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis 2010, 31:427-434.
145. Uefuji K., Ichikura T., Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin. Cancer Res. 2000, 6:135-138.
146. Takafuji V.A., Evans A., Lynch K.R., Roche J.K. PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer.
147. Pockaj B.A., Basu G.D., Pathangey L.B., Gray R.J., Hernandez J.L., Gendler S.J., Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. 2004, 11:328-339.
148. I.M. Toller, I. Hitzler, A. Sayi, A. Mueller, Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model, Gastroenterology 138 (2010) 1455-1467, 1467 e1451-1454.
149. Yuan X.L., Chen L., Li M.X., Dong P., Xue J., Wang J., Zhang T.T., Wang X.A., Zhang F.M., Ge H.L., Shen L.S., Xu D. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin. Immunol. 2010, 134:277-288.
150. Ding Y.B., Shi R.H., Tong J.D., Li X.Y., Zhang G.X., Xiao W.M., Yang J.G., Bao Y., Wu J., Yan Z.G., Wang X.H. PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp. Oncol. 2005, 27:108-113.
151. Hansen-Petrik M.B., McEntee M.F., Jull B., Shi H., Zemel M.B., Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res. 2002, 62:403-408.
152. Kawamori T., Uchiya N., Sugimura T., Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003, 24:985-990.
153. Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., Das S.K., Dey S.K., DuBois R.N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004, 6:285-295.
154. P. Jimenez, E. Piazuelo, C. Cebrian, J. Ortego, M. Strunk, M.A. Garcia-Gonzalez, S. Santander, J. Alcedo, A. Lanas, Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma, Aliment. Pharmacol. Ther. 31 (2010) 440-451.
155. Piazuelo E., Jimenez P., Strunk M., Santander S., Garcia A., Esteva F., Lanas A. Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins Other Lipid Mediat. 2006, 81:150-161.
156. Kuo K.T., Wang H.W., Chou T.Y., Hsu W.H., Hsu H.S., Lin C.H., Wang L.S. Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2009, 16:352-360.
157. Lagergren J., Bergstrom R., Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann. Intern. Med. 1999, 130:883-890.
158. Ogunwobi O., Mutungi G., Beales I.L. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006, 147:4505-4516.
159. Beales I.L., Ogunwobi O.O. Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. J. Mol. Endocrinol. 2009, 42:305-318.
160. Ogunwobi O.O., Beales I.L. Glycine-extended gastrin stimulates proliferation via JAK2- and Akt-dependent NF-kappaB activation in Barrett's oesophageal adenocarcinoma cells. Mol. Cell. Endocrinol. 2008, 296:94-102.
161. Song S., Guha S., Liu K., Buttar N.S., Bresalier R.S. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2007, 56:1512-1521.
162. Iwamoto J., Mizokami Y., Takahashi K., Matsuoka T., Matsuzaki Y. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells. Helicobacter 2008, 13:174-182.
163. Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Ushikubi F., Narumiya S., Sugimura T., Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999, 59:5093-5096.
164. Kawamori T., Kitamura T., Watanabe K., Uchiya N., Maruyama T., Narumiya S., Sugimura T., Wakabayashi K. Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 2005, 26:353-357.
165. Seno H., Oshima M., Ishikawa T.O., Oshima H., Takaku K., Chiba T., Narumiya S., Taketo M.M. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002, 62:506-511.
166. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Oshima M., Taketo M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 2001, 7:1048-1051.
167. Amano H., Hayashi I., Endo H., Kitasato H., Yamashina S., Maruyama T., Kobayashi M., Satoh K., Narita M., Sugimoto Y., Murata T., Yoshimura H., Narumiya S., Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 2003, 197:221-232.
168. Doherty G.A., Byrne S.M., Molloy E.S., Malhotra V., Austin S.C., Kay E.W., Murray F.E., Fitzgerald D.J. Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer 2009, 9:207.
169. Tai H.H., Ensor C.M., Tong M., Zhou H., Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:483-493.
170. Thiel A., Ganesan A., Mrena J., Junnila S., Nykanen A., Hemmes A., Tai H.H., Monni O., Kokkola A., Haglund C., Petrova T.V., Ristimaki A. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin. Cancer Res. 2009, 15:4572-4580.
171. Tatsuwaki H., Tanigawa T., Watanabe T., Machida H., Okazaki H., Yamagami H., Shiba M., Watanabe K., Tominaga K., Fujiwara Y., Oshitani N., Muguruma K., Sawada T., Hirakawa K., Higuchi K., Arakawa T. Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci. 2010, 101:550-558.
172. Backlund M.G., Mann J.R., Holla V.R., Buchanan F.G., Tai H.H., Musiek E.S., Milne G.L., Katkuri S., DuBois R.N. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 2005, 280:3217-3223.
173. Kabashima K., Saji T., Murata T., Nagamachi M., Matsuoka T., Segi E., Tsuboi K., Sugimoto Y., Kobayashi T., Miyachi Y., Ichikawa A., Narumiya S. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 2002, 109:883-893.
174. Cassano G., Gasparre G., Susca F., Lippe C., Guanti G. Lack of effect by prostaglandin F2alpha on the proliferation of the HCT-8 and HT-29 human adenocarcinoma cell lines. Oncol. Rep. 2000, 7:183-186.
175. Qualtrough D., Kaidi A., Chell S., Jabbour H.N., Williams A.C., Paraskeva C. Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. Int. J. Cancer 2007, 121:734-740.
176. Pradono P., Tazawa R., Maemondo M., Tanaka M., Usui K., Saijo Y., Hagiwara K., Nukiwa T. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002, 62:63-66.
177. Gupta R.A., Tan J., Krause W.F., Geraci M., Willson T.M., Dey S.K. Prostacyclin mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13275-13280.
178. Cutler N.S., Graves-Deal R., LaFleur B.J., Gao Z., Boman B.M., Whitehead R.H., Terry E., Morrow J.D., Coffey R.J. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res. 2003, 63:1748-1751.
179. Wu K.K., Liou J.Y. Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARdelta → 14-3-3epsilon pathway. Methods Mol. Biol. 2009, 512:295-307.
180. Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K., DuBois R.N. Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19069-19074.
181. Gustafsson A., Hansson E., Kressner U., Nordgren S., Andersson M., Lonnroth C., Lundholm K. Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol. 2007, 46:1107-1112.
182. Giese A., Hagel C., Kim E.L., Zapf S., Djawaheri J., Berens M.E., Westphal M. Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro Oncol. 1999, 1:3-13.
183. Kajita S., Ruebel K.H., Casey M.B., Nakamura N., Lloyd R.V. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod. Pathol. 2005, 18:221-227.
184. Nie D., Che M., Zacharek A., Qiao Y., Li L., Li X., Lamberti M., Tang K., Cai Y., Guo Y., Grignon D., Honn K.V. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am. J. Pathol. 2004, 164:429-439.
185. Sakai H., Suzuki T., Takahashi Y., Ukai M., Tauchi K., Fujii T., Horikawa N., Minamimura T., Tabuchi Y., Morii M., Tsukada K., Takeguchi N. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett. 2006, 580:3368-3374.
186. Daniel T.O., Liu H., Morrow J.D., Crews B.C., Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 1999, 59:4574-4577.
187. Yokoyama I., Hayashi S., Kobayashi T., Negita M., Yasutomi M., Uchida K., Takagi H. Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. Res. Exp. Med. (Berl.) 1995, 195:209-215.
188. Bing R.J., Miyataka M., Rich K.A., Hanson N., Wang X., Slosser H.D., Shi S.R. Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin. Cancer Res. 2001, 7:3385-3392.
189. Sciulli M.G., Filabozzi P., Tacconelli S., Padovano R., Ricciotti E., Capone M.L., Grana M., Carnevale V., Patrignani P. Platelet activation in patients with colorectal cancer. Prostaglandins Leukot. Essent. Fatty Acids 2005, 72:79-83.
190. Farrow D.C., Vaughan T.L., Hansten P.D., Stanford J.L., Risch H.A., Gammon M.D., Chow W.H., Dubrow R., Ahsan H., Mayne S.T., Schoenberg J.B., West A.B., Rotterdam H., Fraumeni J.F., Blot W.J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1998, 7:97-102.
191. Langman M.J., Cheng K.K., Gilman E.A., Lancashire R.J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320:1642-1646.
192. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53:1322-1327.
193. Harris R.E., Beebe-Donk J., Doss H., Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol. Rep. 2005, 13:559-583.
194. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
195. Das D., Chilton A.P., Jankowski J.A. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009, 181:161-169.
196. Husain S.S., Szabo I.L., Tamawski A.S. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am. J. Gastroenterol. 2002, 97:542-553.
197. Chan A.T., Ogino S., Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356:2131-2142.
198. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., Meade T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
199. Altorki N. COX-2: a target for prevention and treatment of esophageal cancer. J. Surg. Res. 2004, 117:114-120.
200. Dawson S.J., Michael M., Biagi J., Foo K.F., Jefford M., Ngan S.Y., Leong T., Hui A., Milner A.D., Thomas R.J., Zalcberg J.R. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest. New Drugs 2007, 25:123-129.
201. Shamma A., Yamamoto H., Doki Y., Okami J., Kondo M., Fujiwara Y., Yano M., Inoue M., Matsuura N., Shiozaki H., Monden M. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 2000, 6:1229-1238.
202. Yu H.P., Xu S.Q., Liu L., Shi L.Y., Cai X.K., Lu W.H., Lu B., Su Y.H., Li Y.Y. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Lett. 2003, 198:193-201.
203. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999, 59:198-204.
204. Tuynman J.B., Buskens C.J., Kemper K., ten Kate F.J., Offerhaus G.J., Richel D.J., van Lanschot J.J. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann. Surg. 2005, 242:840-849. discussion 849-850.
205. Govindan R., McLeod H., Mantravadi P., Fineberg N., Helft P., Kesler K., Hanna N., Stoner C., Ansari R., Fox E. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park) 2004, 18:18-21.
206. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E.S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 1998, 274:G1061-G1067.
207. Zhang L.J., Wang S.Y., Huo X.H., Zhu Z.L., Chu J.K., Ma J.C., Cui D.S., Gu P., Zhao Z.R., Wang M.W., Yu J. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J. Gastroenterol. 2009, 15:2731-2738.
208. Yanaoka K., Oka M., Yoshimura N., Deguchi H., Mukoubayashi C., Enomoto S., Maekita T., Inoue I., Ueda K., Utsunomiya H., Iguchi M., Tamai H., Fujishiro M., Nakamura Y., Tsukamoto T., Inada K., Takeshita T., Ichinose M. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Int. J. Cancer 2010, 126:1467-1473.
209. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2. Cell 1996, 87:803-809.
210. Davis T.W., O'Neal J.M., Pagel M.D., Zweifel B.S., Mehta P.P., Heuvelman D.M., Masferrer J.L. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004, 64:279-285.
211. Tachimori A., Yamada N., Amano R., Ohira M., Hirakawa K. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res. 2008, 28:629-638.
212. Yan M., Myung S.J., Fink S.P., Lawrence E., Lutterbaugh J., Yang P., Zhou X., Liu D., Rerko R.M., Willis J., Dawson D., Tai H.H., Barnholtz-Sloan J.S., Newman R.A., Bertagnolli M.M., Markowitz S.D. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9409-9413.
213. Midgley R.S., McConkey C.C., Johnstone E.C., Dunn J.A., Smith J.L., Grumett S.A., Julier P., Iveson C., Yanagisawa Y., Warren B., Langman M.J., Kerr D.J. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J. Clin. Oncol. 2010, 28:4575-4580.
214. Helin-Salmivaara A., Virtanen A., Vesalainen R., Gronroos J.M., Klaukka T., Idanpaan-Heikkila J.E., Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur. Heart J. 2006, 27:1657-1663.
215. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
216. D.G. Menter, R.L. Schilsky, R.N. DuBois, Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward, Clin. Cancer Res. 16 (2010) 1384-1390.
217. Chen Y.X., Zhong X.Y., Qin Y.F., Bing W., He L.Z. 15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. World J. Gastroenterol. 2003, 9:2149-2153.
218. Radmark O., Samuelsson B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. J. Intern. Med. 2010, 268:5-14.
219. Schroder O., Yudina Y., Sabirsh A., Zahn N., Haeggstrom J.Z., Stein J. 15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells. J. Lipid Res. 2006, 47:1071-1080.
220. Terzuoli E., Donnini S., Giachetti A., Iniguez M.A., Fresno M., Melillo G., Ziche M. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis. Clin. Cancer Res. 2010, 16:4207-4216.
221. Koeberle A., Northoff H., Werz O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol. Cancer Ther. 2009, 8:2348-2355.
222. Rao C.V., Rivenson A., Simi B., Reddy B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995, 55:259-266.
223. Lev-Ari S., Strier L., Kazanov D., Madar-Shapiro L., Dvory-Sobol H., Pinchuk I., Marian B., Lichtenberg D., Arber N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 2005, 11:6738-6744.
224. Makita H., Mutoh M., Maruyama T., Yonemoto K., Kobayashi A., Fujitsuka H., Toida M., Shibata T., Miyamoto S., Yasui Y., Suzuki R., Wakabayashi K., Tanaka T. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Carcinogenesis 2007, 28:677-684.
225. Arisato T., Hashiguchi T., Sarker K.P., Arimura K., Asano M., Matsuo K., Osame M., Maruyama I. Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region. J. Thromb. Haemost. 2003, 1:2589-2593.
226. Rhee J.S., Black M., Schubert U., Fischer S., Morgenstern E., Hammes H.P., Preissner K.T. The functional role of blood platelet components in angiogenesis. Thromb. Haemost. 2004, 92:394-402.
227. Bick R.L. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J. Support. Oncol. 2006, 4:115-120.
228. Honn K.V., Sloane B.F. Prostacyclin, thromboxanes, and hematogenous metastasis. Adv. Prostaglandin Thromboxane Leukot. Res. 1983, 12:313-318.
229. Pinedo H.M., Verheul H.M., D'Amato R.J., Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet 1998, 352:1775-1777.
230. Boccaccio C., Sabatino G., Medico E., Girolami F., Follenzi A., Reato G., Sottile A., Naldini L., Comoglio P.M. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005, 434:396-400.
231. Rickles F.R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb. 2006, 35:103-110.
232. de Leval X., Benoit V., Delarge J., Julemont F., Masereel B., Pirotte B., Merville M.P., David J.L., Dogne J.M. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukot. Essent. Fatty Acids 2003, 68:55-59.
233. FitzGerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2003, 2:879-890.
234. Andreani A., Burnelli S., Granaiola M., Leoni A., Locatelli A., Morigi R., Rambaldi M., Varoli L., Landi L., Prata C., Berridge M.V., Grasso C., Fiebig H.H., Kelter G., Burger A.M., Kunkel M.W. Antitumor activity of bis-indole derivatives. J. Med. Chem. 2008, 51:4563-4570.
235. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
236. Cespedes M.V., Casanova I., Parreno M., Mangues R. Mouse models in oncogenesis and cancer therapy. Clin. Transl. Oncol. 2006, 8:318-329.
237. Amatruda J.F., Shepard J.L., Stern H.M., Zon L.I. Zebrafish as a cancer model system. Cancer Cell 2002, 1:229-231.
238. Kari G., Rodeck U., Dicker A.P. Zebrafish: an emerging model system for human disease and drug discovery. Clin. Pharmacol. Ther. 2007, 82:70-80.
239. Parng C., Seng W.L., Semino C., McGrath P. Zebrafish: a preclinical model for drug screening. Assay Drug Dev. Technol. 2002, 1:41-48.
240. Stoletov K., Montel V., Lester R.D., Gonias S.L., Klemke R. High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17406-17411.
241. White R.M., Sessa A., Burke C., Bowman T., LeBlanc J., Ceol C., Bourque C., Dovey M., Goessling W., Burns C.E., Zon L.I. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2008, 2:183-189.
242. Marques I.J., Weiss F.U., Vlecken D.H., Nitsche C., Bakkers J., Lagendijk A.K., Partecke L.I., Heidecke C.D., Lerch M.M., Bagowski C.P. Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer 2009, 9:128.
243. Cathcart M.C., Gately K., Cummins R., Kay E., O.B.KJ, Pidgeon G.P. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol. Cancer 2011, 10:25.
244. Jantke J., Ladehoff M., Kurzel F., Zapf S., Kim E., Giese A. Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir. (Wien) 2004, 146:483-494.
245. Moussa O., Yordy J.S., Abol-Enein H., Sinha D., Bissada N.K., Halushka P.V., Ghoneim M.A., Watson D.K. Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res. 2005, 65:11581-11587.
246. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.